ClinicalTrials.gg

Program

elifibranor

Also written as “Elafibranor”, “GFT505 80mg” and “elafibranor”.

Its studies are mostly in Liver Cirrhosis, Biliary · Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Feb 16, 201624 company-led studies, 5 open or runningNext primary completion: Dec 17, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfit160 open or runningphase 3since Feb 16, 2016Dec 13, 2010none ahead
Ipsen85 open or runningphase 3since Aug 21, 2020Aug 21, 2020Dec 17, 2026phase 3 · NCT06730061

Also a collaborator on its studies: naturalpha, premier-research-group-plc, eurofins-optimed and phinc-development.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Dec 13, 2010.

  1. Mar 28, 2017Phase 2 study in Liver Cirrhosis, BiliaryGenfit · NCT03124108 · 45 enrolled · United States, France, Germany and more
  2. Nov 30, 2018Phase 1 study in Liver DiseasesGenfit · NCT03765671 · 30 enrolled · United States
  3. Feb 15, 2019Phase 1 study in Renal InsufficiencyGenfit · NCT03844555 · 23 enrolled · France, Romania
  4. Mar 13, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseGenfit · NCT03883607 · 10 enrolled · United States
  5. May 15, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseGenfit · NCT03953456 · 17 enrolled · Netherlands
  6. Jun 11, 2019Phase 1 study in Drug-drug InteractionGenfit · NCT03985969 · 26 enrolled · France
  7. Nov 19, 2019Phase 1 study in GeriatricsGenfit · NCT04171752 · 21 enrolled · France
  8. Aug 21, 2020Ipsen's first study: phase 3 study in Liver Cirrhosis, BiliaryNew to IpsenIpsen · NCT04526665 · 161 enrolled · United States, Argentina, Belgium and more
  9. Sep 14, 20222 phase 1 studiesIpsen · NCT05543369, NCT05564208
  10. Nov 22, 2022Phase 2 study in Cholangitis, SclerosingIpsen · NCT05627362 · 68 enrolled · United States, Canada, Germany and more
  11. Aug 22, 2023Phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06016842 · 276 planned · United States, Argentina, Australia and more
  12. Apr 22, 2024Phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06383403 · 92 enrolled · United States, Czechia, France and more
  13. Dec 3, 2024Phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06730061 · 18 enrolled · Japan
  14. Jan 28, 2026Phase 3 study in Cholangitis, SclerosingIpsen · NCT07387549 · 350 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 17, 2026Primary completion: phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06730061
  2. May 31, 2029Primary completion: phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06016842
  3. Apr 30, 2031Primary completion: phase 3 study in Cholangitis, SclerosingIpsen · NCT07387549
  4. Sep 23, 2031Primary completion: phase 2 study in Cholangitis, SclerosingIpsen · NCT05627362

TargetBeta

PPARA →PPARD →read by rule
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-alpha (PPARa) and -delta (PPARd), with bile acids reducing activity”NCIt, by rule
“Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
seladelparruleGilead Sciencesphase 314
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07387549Cholangitis, Sclerosing · United States, Argentina, Australia and more3RecruitingIpsenApr 30, 2031350
NCT06730061Liver Cirrhosis, Biliary · Japan3Active, not recruitingIpsenDec 17, 202618
NCT06383403Liver Cirrhosis, Biliary · United States, Czechia, France and more3CompletedIpsenJun 16, 202692
NCT06016842Liver Cirrhosis, Biliary · United States, Argentina, Australia and more3RecruitingIpsenMay 31, 2029276
NCT05627362Cholangitis, Sclerosing · United States, Canada, Germany and more2Active, not recruitingIpsenSep 23, 203168
NCT05564208Healthy Participants · France1CompletedIpsenDec 30, 202234
NCT05543369Healthy Volunteers · United States1CompletedIpsenMar 10, 202348
NCT04526665Liver Cirrhosis, Biliary · United States, Argentina, Belgium and more3Active, not recruitingIpsenJun 1, 2023161
NCT04171752Geriatrics · France1CompletedGenfitMar 22, 202021
NCT03985969Drug-drug Interaction · France1CompletedGenfitMar 15, 202026
NCT03953456Non-alcoholic Fatty Liver Disease · Netherlands2TerminatedGenfitMar 11, 202017
NCT03883607Non-alcoholic Fatty Liver Disease · United States2TerminatedGenfitJun 16, 202010
NCT03844555Renal Insufficiency · France, Romania1CompletedGenfitMar 15, 202023
NCT03765671Liver Diseases · United States1CompletedGenfitJun 7, 201930
NCT03124108Liver Cirrhosis, Biliary · United States, France, Germany and more2CompletedGenfitOct 31, 201845
NCT02704403Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3TerminatedGenfitOct 28, 20202,157
NCT02142127Healthy · Belgium1CompletedGenfitJun 20146
NCT02091310Healthy Volunteers · France1CompletedGenfitDec 2014200
NCT01694849Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more2CompletedGenfitFeb 2015275
NCT01474161Diabetes Mellitus, Type 2 · France1CompletedGenfitNov 201296
NCT01275469Glucose Intolerance · France2CompletedGenfitDec 200947
NCT01271751Obesity, Abdominal · France, Romania, Tunisia2CompletedGenfitSep 200996
NCT01271777Insulin Resistance · France2CompletedGenfitNov 201122
NCT01261494Diabetes Mellitus, Type 2 · Bosnia and Herzegovina, Latvia, Macedonia, The Former Yugoslav Republic of and more2CompletedGenfitJun 201197

How it is read

Names in the registry

  • “Elafibranor”, 8 entries
  • “GFT505 80mg”, 5 entries
  • “elafibranor”, 4 entries
  • “Elafibranor 80mg”, 2 entries
  • “Elafibranor 80 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.